BioSpace News Archive

SKYSONA is the first and only gene therapy recommended for approval for patients with CALD, a progressive, neurodegenerative disease As of the data cutoff date, 90% of patients (27/30) treated with SKYSONA in the pivotal ALD-102 clinical study met the primary endpoint of major functional disability (MFD)-free survival at two years of follow-up

VBI Vaccines Inc. ( Nasdaq: VBIV ) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced an agreement to drawdown a $12 million second tranche under its previously announced debt financing facility with K2 HealthVentures (K2HV), a healthcare-focused specialty finance company. Under the terms of the debt financing facility, dated May 22, 2021

Transparency Market Research has published a new report titled, “Surgical Drills Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”.According to the report, the global surgical drills market was valued at US $ 412.6 Mn in 2017.

Transparency Market Research finds that players in the global Platelet Incubator Market are ramping their investments in several expansion strategies to gain a competitive edge.

PARP Inhibitors are the medications, which hinder the chemical called poly ADP ribose polymerase. PARP inhibitors produced for treating a few maladies, the most critical one is malignant growth.

Transparency Market Research has published a new report titled, “Pharmaceutical Waste Management Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”.

The global microdermabrasion devices market was valued at around US$ 150 Mn in 2017.

Disposable EEG electrodes are gaining preference in EEG, EP, and PSG examinations. The use of reusable EEG cup electrodes continues to lose sheen on the back of growing awareness about the risk of healthcare associated infections across patients and healthcare workers.

Randomized controlled trial in the US and Europe will enable LIQOSEAL® to be submitted for FDA approval

Increasing use of combination therapy such as ezetimibe and fibrates therapy is likely to boost the growth of the hypercholesterolemia treatment market.